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plex then initiates transcription. The ability to selectivelyUnderstanding Diseases
bind one NR isoform to a SRC would allow the unravelingvia Receptor Regulation of individual signaling pathways for that NR and SRC
complex. There are three known SRCs: SRC1, SRC2,
and SRC3 [3–5]. They appear to play distinct but, per-
haps, partially overlapping functions [4, 6]. The NRs bindIn this issue of Chemistry & Biology, Guy and cowork-
to an area of a SRC protein known as the nuclear recep-ers [11] demonstrate that they can selectively recruit
tor-interacting domain (NID). This NID area contains mul-individual nuclear receptors by using small molecules
tiple, conserved interfaces that have identical se-(proteomimetics) in combination with specific ago-
quences specific for each SRC, which are known as NRnists. This may ultimately lead to a link between the
boxes. The NR boxes contain sequences of the motifreceptor’s signaling pathway and its role in individual
L1XXL2L3, [1, 2], where L depicts a position of diversity,diseases.
and X is an amino acid specific to that SRC. Thus, for
example, the SRC2 NR box contains multiple, conservedA number of diseases, including cancer and metabolic
interfaces within the NID that are sequence LERLL.disorders, are known to be associated with the inappro-
One series of structurally similar NRs are two isoformspriate regulation of the nuclear hormone receptor tran-
of estrogen receptors: ER and ER. Both ER and ERscription factors (NRs). [1] NRs regulate transcription
bind to SRC2 to activate transcription. However, theybased on hormone levels. The complex mechanisms
regulate entirely different gene transcription pathwaysinvolved in these signaling pathways are poorly under-
[7]. Both ER and ER bind to the second box of SRC2stood. Selectively examining each nuclear receptor’s
(SRC2-2) in the presence of a number of agonists, in-signaling pathway will provide insight into their connec-
cluding estradiol, diethyl stilbesterol, or genistein.tion to specific diseases.
In earlier work using a small molecule library of com-Uncoupling the signaling pathways of these NRs is
pounds that mimicked the second SRC2 NR box (SRC2-challenging. The ability to selectively activate one NR
2), Guy and coworkers discovered a small molecule pro-in the presence of other NRs using small molecules has
teomimetic that selectively blocked binding of ER inbeen limited by the similarity of one NR isoform over
the presence of ER to SRC2 [8]. Thus transcriptionanother and the challenge of replacing a protein-protein
regulation by ER was inhibited in the presence of ER,interaction with a small molecule-protein interaction.
while transcription regulated by ER was unaffected. InUpon discovery of lead small molecules, compound li-
addition, they found a proteomimetic that could prefer-braries targeted to individual NRs could be screened
entially inhibit the binding of ER to SRC2 in the pres-for their specificity for each NR. The discovery of unique
ence of ER. This new tool for selectively inhibiting indi-small molecule leads for each NR would offer selective
vidual NRs using a small molecule for regulating nuclearcontrol of the signaling pathways for the individual nu-
receptors is an excellent lead for the development ofclear receptor, illuminating the connection between the
small, drug-like compounds that will ultimately illumi-specific signals regulating the pathways and the disease
nate the function of these individual receptors.state.
This issue of Chemistry & Biology includes an articleNRs bind to small molecule agonists: hormones.
by Guy and coworkers that demonstrates how smallThese hormones activate the NRs, leading the NR•ago-
molecule proteomimetics can be used to selectively re-nist complex to recruit a specific steroid receptor coacti-
vator (SRC)[1, 2] (Figure 1). This NR•agonist•SRC com- cruit individual NRs that are specific to the hormone
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Figure 1. Ligand-Dependent Nuclear Receptor Regulatory Transcription Complex Assembly
This is Figure 1 from Geistlinger et al. [11].
agonist [11]. They show that two NR receptors, ER eralized where one can envision screening small mole-
cule “NR box” libraries in search of tools that will eventu-and ER, bind to the same agonist ligand, which then
exposes distinctive structural areas of that NR•agonist ally uncouple the function of all NRs. This will allow the
selective regulation of individual NRs and, therefore,complex to the SRC2 NID (i.e., NR box). Using a NR box
reveal the connection between individual transcriptionproteomimetic they had developed earlier [8], Guy and
regulation of these NRs and their associated diseases.coworkers demonstrate selective recruitment of either
ER or ER with the same agonist hormone. These pro-
teomimetic NR boxes were shown to selectively inhibit Shelli R. McAlpine
the binding of SRC2 to the ER•agonist complex over Department of Chemistry
the ER•agonist complex, preferentially forming the ER- San Diego State University
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suppresses RNA silencing and a 21 nucleotide smallHow to Silence Silencing
interfering (si)RNA.
RNA silencing is part of an innate defense strategy
against viruses in plants [3]. Both suppressor proteinsTwo recent reports [1, 2] describe the stunning crystal
structures of complexes between a viral protein that come from plant viruses belonging to the Tombusvirus
